Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;43(10):1084-1092.
doi: 10.1002/clc.23432. Epub 2020 Aug 14.

State-of-the-art consensus on non-transvenous implantable cardioverter-defibrillator therapy

Christoph Schukro  1 , David Santer  2 , Günther Prenner  3 , Markus Stühlinger  4 , Martin Martinek  5 , Alexander Teubl  6 , Deddo Moertl  7 , Stefan Schwarz  8 , Michael Nürnberg  9 , Lukas Fiedler  6 , Robert Hatala  10 , Cesar Khazen  11
Affiliations
Review

State-of-the-art consensus on non-transvenous implantable cardioverter-defibrillator therapy

Christoph Schukro et al. Clin Cardiol. 2020 Oct.

Abstract

Within the last decade, implantable cardioverter-defibrillator (ICD) systems with non-transvenous leads were developed in order to minimize complications related to the cardiovascular position of transvenous ICD leads. This national expert consensus gives an overview of potential indications for the implantation of non-transvenous ICD systems, and provides specific recommendations for implantation, follow-up, and complication management in patients with subcutaneous ICD. Regarding particular issues like the necessity for shock efficacy testing, or the clinical outcome as compared to transvenous ICD, randomized data are expected in the near future.

Keywords: consensus document; non-transvenous implantable cardioverter defibrillator; recommendations; subcutaneous implantable cardioverter defibrillator.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Most frequent underlying diseases in S‐ICD patients depending on primary and secondary prevention. ARVD, arrhythmogenic ventricular dysplasia; dCMP, dilated cardiomyopathy; HCMP, hypertrophic cardiomyopathy; iCMP, ischemic cardiomyopathy (ischemic LV dysfunction); IVF, idiopathic ventricular fibrillation; LQTS, long‐QT syndrome; S‐ICD, subcutaneous implantable cardioverter‐defibrillator; TGA, transposition of great arteries
FIGURE 2
FIGURE 2
Most frequent indications for S‐ICD implantation depending on primary and secondary prevention. dCMP, dilated cardiomyopathy; HCMP, hypertrophic cardiomyopathy; iCMP: ischemic cardiomyopathy (ischemic LV dysfunction); LQTS, long‐QT syndrome; SCD, sudden cardiac death; S‐ICD, subcutaneous implantable cardioverter‐defibrillator; VT, ventricular tachycardia
See this image and copyright information in PMC

References

    1. Schuder JC, Stoeckle H, Gold JH, West JA, Keskar PY. Experimental ventricular defibrillation with an automatic and completely implanted system. Trans Am Soc Artif Intern Organs. 1970;16:207‐212. - PubMed
    1. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter‐defibrillator. JAMA. 2009;301:1661‐1670. - PMC - PubMed
    1. Chan JYS, Lelakowski J, Murgatroyd FD, et al. Novel extravascular defibrillation configuration with a coil in the substernal space: the ASD Clinical Study. JACC Clin Electrophysiol. 2017;3:905‐910. - PubMed
    1. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter‐defibrillator. N Engl J Med. 2010;363:36‐44. - PubMed
    1. Sponder M, Khazen C, Dichtl W, et al. Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter‐defibrillator (ICD)‐a nationwide multicentre registry. Eur J Intern Med. 2018;48:64‐68. - PubMed